In his interview at ESMO 2018, Dr Ian Chau discusses the RAINFALL trial, a randomised, double-blind, placebo-controlled phase III trial to assess the combination of cisplatin plus capecitabine/5-fluorouracil chemotherapy with ramucirumab (a monoclonal antibody against VEGFR2) in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. A total of 645 patients were randomised to cisplatin plus capecitabine/5-fluorouracil chemotherapy with ramucirumab, or cisplatin plus capecitabine/5-fluorouracil chemotherapy with placebo. Dr Chau explains the results of the trial and their implications, and provides an insight into the quality-of-life outcomes and how these are translated into clinical practice. He also discusses the limitations of the trial, which are largely geographical, based on the demographic of the disease and difference in standard of care between different countries. Finally, he suggests how the results of this trial, and other recent trials, may shape future of clinical trials with ramucirumab and the treatment landscape.
1. Could you tell us a little about the rationale and design of the RAINFALL study? (0:11)
2. What were the main efficacy and safety findings of the study? (1:51)
3. What were the quality of life findings from the study? (2:44)
4. What were the limitations of this study (7:36)?
5. What are the next steps in the clinical development of ramucirumab in the second-line treatment of gastric and gastroesophageal adenocarcinoma? (8:55)
Speaker disclosures: Ian Chau has nothing to disclose in relation to this interview.
Filmed at the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, 19–23 October 2018.
Share this Video
Related Videos In Gastrointestinal Oncology
Angela Lamarca, ESMO 2022: ABC-06 trial, quality of life results – Symptom-control with FOLFOX in the treatment of advanced biliary cancers
The ABC-06 clinical trial established active-symptom control + oxaliplatin/5-FU chemotherapy (FOLFOX) as the standard of care treatment after Cisplatin and Gemcitabine for advanced biliary cancers. Dr Angela Lamarca (Fundación Jiménez Diaz University Hospital, Madrid, Spain) joins touchONCOLOGY to discuss the efficacy and safety of second-line active- symptom-control with FOLFOX, and the quality of life and […]
Alvaro Arjona-Sanchez, ESMO 2022: HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant HIPEC in patients with locally advanced colon cancer
Peritoneal metastasis in locally advanced colon cancer has a poor prognosis from 3 years post surgical resection. Dr Alvaro Arjona-Sanchez (Institute of Biomedical Research IMIBIC, University Hospital Reina Sofia, Cordoba, Spain) joins touchONCOLOGY to discuss the HIPECT4 phase 3 trial investigating the efficacy and safety of adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with locally […]
Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: the NICHE-2 study
Neoadjuvant immunotherapy has shown promising responses in several cancer types. In this touchONCOLOGY interview Dr Myriam Chalabi (Netherlands Cancer Institute, Amsterdam, Netherlands) discusses the NICHE-2 study results, investigating patients with non-metastatic deficient DNA mismatch repair (dMMR) colon cancer, treated with one dose of ipilimumab and two doses of nivolumab and underwent surgery ≤6 weeks of […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!